 | 
| ||
| home > Aurobindo Pharma > news | |||
| Aurobindo Pharma receives approval for Citalopram Hydrobromide tablets from TGA, Australia | |||
| 18 Dec 2009
: Aurobindo Pharma Limited is pleased to announce that its wholly owned subsidiary Aurobindo Pharma Australia Pty Ltd has received approval from Therapeutic Goods Administration (TGA), Government of Australia for the registration of Citalopram Hydrobromide Tablets 10mg, 20mg & 40mg. Citalopram Hydrobromide Tablets are indicated for the treatment of depression and fall under the Central Nervous System (CNS) therapeutic segment. This is Aurobindo's fifth approval from TGA, Australia. About Aurobindo Pharma Limited: Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti - Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries. |
|||
| | ||
| home > Aurobindo Pharma > news | |||
 |
|||
| |||